CardioPulmonary Vascular Biology COBRE

心肺血管生物学 COBRE

• 批准号: 10630735
• 负责人: Gaurav Choudhary
• 金额: $ 91.35万
• 依托单位: OCEAN STATE RESEARCH INSTITUTE, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-01 至 2028-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10630735
• 关键词: 2019-nCoV; Advisory Committees; Affect; Area; Award; Biology; Blood Vessels; COVID-19 pandemic; Cardiopulmonary; Cardiovascular Diseases; Cardiovascular system; Cause of Death; Cell Separation; Centers of Research Excellence; Collaborations; Communities; Coronary Arteriosclerosis; Data; Development; Discipline; Disease; Educational workshop; Feedback; Fostering; Funding; Goals; Growth; Home; Human; Infection; Infrastructure; Institution; Investigation; Learning; Legal patent; Lung; Lung diseases; Manuscripts; Mission; Mitochondria; Morbidity - disease rate; Organ; Pathogenesis; Phase; Pilot Projects; Prevention; Productivity; Prognosis; Publishing; Research; Research Personnel; Research Project Grants; Resources; Respiratory Disease; Rhode Island; Scientist; Services; Structure; Vascular Diseases; Virus; Vision; career; catalyst; combat; comorbidity; effective therapy; in vivo imaging; mortality; prevent; programs; pulmonary vascular disorder; respiratory

The vision of the CardioPulmonary Vascular Biology (CPVB) COBRE program is to develop effective approaches to prevent and treat vascular diseases affecting the pulmonary and cardiovascular systems through better understanding of disease mechanisms. This will be accomplished by serving as an interdisciplinary center which promotes collaborative research and provides excellent technical support and resources to investigators. The overall mission of the CPVB COBRE program has been to build the human and technical infrastructure and services that serve as catalysts to increase CPVB research in the state. Cardiovascular and pulmonary diseases are among the leading causes of morbidity and mortality in the US and in the world. Coronary artery disease (CAD) is the leading cause of morbidity and mortality. Respiratory diseases are the 3rd and 4th leading causes of death and are frequently complicated by pulmonary vasculopathy and cardiovascular co-morbidities that markedly worsen prognosis. We have learned that infection with SARS-CoV-2 virus damages multiple organs, with cardiovascular, respiratory, and vascular complications. Thus, there is an important need to understand the pathogenesis of cardiopulmonary vascular diseases in order to develop more effective treatments and prevention. The overall goal of the CPVB COBRE program is to facilitate high impact vascular biology research. The CPVB COBRE program provides infrastructure with administrative, pilot project, and two technical cores, thus providing opportunities to expand areas of investigation, experimental and technical approaches, and scientific collaborations. The specific aims of Phase III CPVB COBRE are to: i) award high-impact research projects in the area of cardiopulmonary vascular biology; ii) provide effective and high-quality services in cell isolation and ex vivo organ function (CIOF), mitochondrial function, and in vivo imaging (MF-II); iii) collaborate with IDeA programs in Rhode Island (RI) and other states to foster scientific networks by providing programming, funding, technical services, and resources to enhance research productivity; and iv) maintain a robust line of investigation in vascular biology that meets the needs of the scientific community and furthers research in prevention and treatment of cardiopulmonary vascular diseases. Continuation of the CPVB COBRE into Phase III will sustain the administrative structure for seminars and workshop planning, engagement, and professional development support of investigators, and expertise in cell isolation and ex vivo organ function, mitochondrial function, and in vivo imaging. We will expand and enrich the vascular biology research community by promoting new collaborations and engaging scientists new to the field from a variety of disciplines. At the end of Phase III, we expect to transition to a sustainable CPVB Center serving as a home to the CVPB research community with high quality core services, significant institutional support, and commitment to continue the development of effective approaches to combat or resolve cardiopulmonary vascular diseases.

心肺血管生物学(CPVB)COBRE计划的愿景是开发有效的方法 通过更好地预防和治疗影响肺和心血管系统的血管疾病 对疾病机制的理解。这将通过充当一个跨学科中心来实现，该中心 促进合作研究，为调查人员提供优秀的技术支持和资源。这个 CPVB Cobre计划的总体任务是建立人力和技术基础设施，并 作为催化剂的服务，在该州增加CPVB研究。心血管和肺部疾病 是美国和世界上发病率和死亡率的主要原因之一。冠状动脉疾病 冠心病是发病率和死亡率的主要原因。呼吸道疾病是第三和第四大致病原因 常合并肺血管病变和心血管合并症 明显恶化预后。我们了解到，感染SARS-CoV-2病毒会损害多个器官， 有心血管、呼吸系统和血管并发症。因此，有必要了解 心肺血管疾病的发病机制，以开发更有效的治疗方法和 预防。CPVB Cobre计划的总体目标是促进高影响力的血管生物学研究。 CPVB Cobre计划为基础设施提供管理、试点项目和两个技术核心， 从而提供了扩大调查、试验和技术方法领域的机会，以及 科学合作。CPVB Cobre第三阶段的具体目标是：i)奖励高影响力的研究 心肺血管生物学领域的项目；二)在细胞内提供有效和高质量的服务 分离和体外器官功能(CIOF)、线粒体功能和体内成像(MF-II)；iii)合作 通过在罗德岛(RI)和其他州实施IDEA计划，通过提供编程来培育科学网络， 资金、技术服务和资源，以提高研究效率；以及四)保持强有力的 满足科学界需要的血管生物学研究，并进一步研究 防治心肺血管疾病。CPVB Cobre进入阶段的延续 III将维持研讨会和研讨会的行政结构，包括规划、参与和专业 研究人员的开发支持，以及在细胞分离和体外器官功能、线粒体方面的专业知识 功能，以及活体成像。我们将通过促进和促进血管生物学研究社区的扩大和丰富 新的合作和吸引来自不同学科的新领域科学家的参与。在第三阶段结束时， 我们希望过渡到一个可持续的CPVB中心，作为CVPB研究社区的家园， 高质量的核心服务，重要的机构支持，并致力于继续发展 防治或解决心肺血管疾病的有效方法。